◎ Sugi Atlas

Atlas / Disease / Anterior ischemic optic neuropathy

Anterior ischemic optic neuropathy

disease
On this page

Also known as aionischaemic optic neuropathyischemic optic neuropathyoptic disc infarction leading to vision loss

Summary

Anterior ischemic optic neuropathy (MONDO:0006649) is a disease and 18 clinical trials. Top therapeutic interventions include timolol, alprostadil, and bosentan. A subtype of optic nerve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameanterior ischemic optic neuropathy
Mondo IDMONDO:0006649
EFOEFO:1000809
MeSHD018917
DOIDDOID:12010
ICD-11632323575
SNOMED CT404659001
UMLSC0751711
MedGen199716
GARD0009790
MedDRA10068250
Is cancer (heuristic)no

Also known as: aion · ischaemic optic neuropathy · ischemic optic neuropathy · optic disc infarction leading to vision loss

Disease family

This is a subtype of optic nerve disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › optic nerve disorder › anterior ischemic optic neuropathy

Related subtypes (7): optic disk drusen, optic nerve neoplasm, optic atrophy, optic neuritis, low tension glaucoma, extensive peripapillary myelinated nerve fibers, isolated optic nerve aplasia

Subtypes (2): arteritic anterior ischemic optic neuropathy, non-arteritic anterior ischemic optic neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
BosentanPhase 3 (in late-stage trials)
MethylprednisolonePhase 3 (in late-stage trials)
OxygenPhase 3 (in late-stage trials)
Triamcinolone AcetonidePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alprostadil, Bevacizumab, Epoetin Beta.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified12
PHASE32
PHASE12
PHASE41
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00867815PHASE4TERMINATEDPDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT00000127PHASE3COMPLETEDIschemic Optic Neuropathy Decompression Trial (IONDT)
NCT02377271PHASE3UNKNOWNENDOTHELION Study Group: Effect of Bosentan in NAION Patients
NCT03851562PHASE2UNKNOWNIntravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy
NCT01411657PHASE1COMPLETEDNT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
NCT01607671PHASE1WITHDRAWNTreatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
NCT03475173Not specifiedRECRUITINGNew Non-invasive Modalities for Assessing Retinal Structure and Function
NCT05749094Not specifiedRECRUITINGOptic Nerve Sheath Ultrasound in Giant Cell Arteritis
NCT06500728Not specifiedRECRUITINGVisual Involvement in Giant Cell Arteritis
NCT06748703Not specifiedRECRUITINGOptic Nerve Injury in Obstructive Sleep Apnea Patients
NCT07206238Not specifiedRECRUITINGOrbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
NCT00000126Not specifiedUNKNOWNIschemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
NCT00450294Not specifiedCOMPLETEDIntraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair
NCT01260324Not specifiedCOMPLETEDEpidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT01768260Not specifiedUNKNOWNEffect of EECP on Anterior Ischemic Optic Neuropathy
NCT02643615Not specifiedCOMPLETEDSafety and Efficacy of Using SightSaver Visual Evoked Potential (VEP) for VEP Monitoring in Prone Spine Surgery
NCT03401892Not specifiedCOMPLETEDRetinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy
NCT05353413Not specifiedUNKNOWNDiffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
TIMOLOL43
ALPROSTADIL41
BOSENTAN41
DESFLURANE41
FLUORESCEIN41
CHEMBL17775601

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogardgenccgwasgwas_studyhgncicd11meddramedgenmeshmimmondomondochildmondoparentorphanetsctidumls